{"product_id":"survodutide","title":"Survodutide","description":"\u003ch2\u003e\u003cstrong\u003eSURVODUTIDE GLP-1 \u0026amp; METABOLIC\/\nWEIGHT LOSS PEPTIDES\u003c\/strong\u003e\u003c\/h2\u003e\n\n\u003cp\u003eSurvodutide is an investigational, highly potent dual-receptor agonist that represents a major\nbreakthrough in the treatment of severe obesity and metabolic liver diseases. Co-invented by\nBoehringer Ingelheim and Zealand Pharma, it uniquely activates both the Glucagon-Like Peptide-1\n(GLP-1) and Glucagon (GCG) receptors simultaneously. This dual-hormone strategy is designed not\nonly to powerfully suppress appetite and reduce caloric intake but also to actively stimulate\ncellular energy expenditure and directly clear fat from the liver. Administered as a weekly injection,\nSurvodutide is setting new benchmarks in clinical trials, particularly for patients suffering from\nobesity combined with Metabolic Dysfunction-Associated Steatohepatitis (MASH).\u003c\/p\u003e","brand":"PeptideValidation.com","offers":[{"title":"Default Title","offer_id":46458101891269,"sku":null,"price":0.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0787\/1515\/8725\/files\/Survodutide.png?v=1782826297","url":"https:\/\/peptidevalidation.com\/products\/survodutide","provider":"PeptideValidation.com","version":"1.0","type":"link"}